Member Info for technick

Off c19 topic but interesting US DOD poster on the Genedrive website. The DOD have ordered another 500 units so must like what genedrive offers them as a product range. I suspect with assays this is a £mm order and provides significant financial support later this year.

https://www.genedrive.com/documents/verification-and-validation-of-genedrive-bioplex.pdf

Scart, 5th key design feature. They wouldn’t use the word validated wrongly imo

Genedrive SARS-cov-2
Validated sample types
Nasopharyngeal swabs and Oropharyngeal swabs

Scart, the website already refers to swabs being validated... I think they’re further ahead than we see

agreed, all looks really positive

I think it will be based around market cap and sales. NCTY are already booking £90m of sales and they are not even touching the sides of the potential here. If GDR post similar revenues in excess of £100m then £140m to £160m seems reasonable as its not close to 5x sales which would be the normal metric...

Hi Marve, the big difference between GDR and NYCT is that GDR partner their sales. NYCT are suppliers of test kits where as GDR create complete systems. Their HCV test is sold through Sysmex, a large Japanese company with a much bigger reach than GDR can obtain on their own. This maximises their ability to get into market and takes away a lot of overhead. I suspect either Sysmex or Cytiva are lined up to take the test to market, giving GDR instant world wide sales and distribution. As a LTH I have constantly being saying along with others who sadly are not posting at the moment (CW hope you are ok) that a trade sale is a likely exit strategy for GDR. I don't know if C19 makes that more or less of a route now, but time will tell I guess. Exciting times, GDR has world class partners already...

my gut feel is we will see something commercial next and not technical, the test is a slam dunk in development terms and as I've mentioned before the website already refers to samples being validated ie working with clinical samples as its a technical term. So the test is a given, also the RNSs only referent to availability of components as the risk. So my opinion is we will see a tie up in whatever for that takes for commercialisation next... hopefully next week, possibly the week after

I agree alwaysone, I think development is a co-development with shared risk and a discussion around sales and distribution is happening to provide the test world wide, Genedrive are also on the record saying they'll need to find a partner. Co-development is reducing costs.

I feel a big week coming next week... One of our RNS predictions at least

#here, auto correct!

yes in my opinion, its why we are hear

what's your target Punit?

Generally UK represents 3% of the ROW. Daily test requirements likely to be into the m's world wide.

It is not clear if a vaccine will be successful. The common cold for example is a coronavirus too, and it doesn't have a vaccine. Influenza changes every year so vaccines need to be continually made to the different strains, this happens due to mutations. SARS-CoV-2 is mutating and it is likely the longer this goes on and the distribution world wide that this will become a longer term issue.

testing is going to be here for a long time

listen to...
https://www.bloomberg.com/news/videos/2020-04-29/coronavirus-testing-still-has-a-long-way-to-go-johns-hopkins-sauer-video

sorry, my poor sense of humour and the random questions from others over the week, quiet day!

what does 'you' mean bigbench?

I'm not sure whee people are getting the idea lockdown is nearly over, I don't think anything government has said would give that impression, to the contrary they have been candid enough to say if and when lockdown restrictions are eased there will need to be significant restrictions in place and testing needed

Agreed, the MMs keeping a tight spread on this so it's all fair trading, expect this to recover over the course of the days as there is good support at this level imo

It is interesting, and this testing is only restricted to people with symptoms or recovering because of the availability of tests. Ideally they'd also be test asymptomatic patients which from reading cold be 40-60% higher than the recorded positives. It's this group that need testing to prevent second, third and recurring waves

Agree with Olderandwiser, but long term a takeover will happen here simply because in this industry there are few companies that are not bought by the larger diagnostic players, it’s how they keep their product lines fresh and innovative. Once the current SARS test is on-market I suspect there will be suitors particularly as it supports the underlying technology developed by the company for POC in addition to the lab based tests. It’s a nice package.